Scarica l'app Stockscreener
19.19
3.62%
-0.72
Dopo l'orario di chiusura:
19.25
0.06
+0.31%
Precedente Chiudi:
$19.91
Aprire:
$19.7
Volume 24 ore:
1.82M
Relative Volume:
0.77
Capitalizzazione di mercato:
$3.73B
Reddito:
$1.14B
Utile/perdita netta:
$-250.98M
Rapporto P/E:
-14.11
EPS:
-1.36
Flusso di cassa netto:
$-251.61M
1 W Prestazione:
-11.77%
1M Prestazione:
-7.12%
6M Prestazione:
-1.89%
1 anno Prestazione:
-42.67%
Intervallo 1D:
$19.15
$19.88
Intervallo di 1 settimana:
$19.15
$21.97
Portata 52W:
$16.24
$37.50
Legend Biotech Corp Adr Stock (LEGN) Company Profile
Nome
Legend Biotech Corp Adr
Settore
Industria
Telefono
-
Indirizzo
-
Compare LEGN vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LEGN
Legend Biotech Corp Adr
|
19.19 | 3.87B | 1.14B | -250.98M | -251.61M | -1.36 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Legend Biotech Corp Adr Stock (LEGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-12 | Downgrade | Rothschild & Co Redburn | Buy → Neutral |
| 2026-01-22 | Downgrade | TD Cowen | Buy → Hold |
| 2026-01-07 | Iniziato | Oppenheimer | Outperform |
| 2025-10-07 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-10-08 | Iniziato | Redburn Atlantic | Buy |
| 2024-06-17 | Iniziato | Truist | Buy |
| 2024-05-24 | Reiterato | H.C. Wainwright | Buy |
| 2024-05-23 | Iniziato | Deutsche Bank | Buy |
| 2024-04-17 | Aggiornamento | Scotiabank | Sector Perform → Sector Outperform |
| 2024-04-03 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-03-13 | Iniziato | Raymond James | Outperform |
| 2023-12-19 | Iniziato | Scotiabank | Sector Perform |
| 2023-11-06 | Iniziato | Goldman | Buy |
| 2023-05-25 | Iniziato | William Blair | Mkt Perform |
| 2023-05-22 | Iniziato | Daiwa Securities | Buy |
| 2023-03-29 | Iniziato | H.C. Wainwright | Buy |
| 2023-03-24 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-12-06 | Iniziato | UBS | Buy |
| 2022-11-02 | Iniziato | Evercore ISI | Outperform |
| 2022-11-01 | Iniziato | Cowen | Outperform |
| 2022-10-31 | Iniziato | Guggenheim | Neutral |
| 2022-06-17 | Iniziato | BMO Capital Markets | Outperform |
| 2022-03-15 | Iniziato | Barclays | Overweight |
| 2022-01-31 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-01-06 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-21 | Iniziato | Piper Sandler | Overweight |
| 2021-05-18 | Iniziato | BTIG Research | Buy |
| 2020-07-01 | Iniziato | JP Morgan | Overweight |
| 2020-07-01 | Iniziato | Jefferies | Buy |
| 2020-06-30 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Legend Biotech Corp Adr Borsa (LEGN) Ultime notizie
H.C. Wainwright reiterates Legend Biotech stock rating at buy - Investing.com
Legend Biotech (LEGN) Institutional Ownership 2026 - MarketBeat
Legend Biotech (NASDAQ: LEGN) targets 19.1M new stock awards - Stock Titan
Legend Biotech (NASDAQ:LEGN) Trading Down 5.3% Following Analyst Downgrade - MarketBeat
Oppenheimer downgrades Legend Biotech stock rating on M&A concerns - Investing.com
Oppenheimer downgrades Legend Biotech stock rating on M&A concerns By Investing.com - Investing.com South Africa
Why is Legend Biotech stock sliding today? - Investing.com
Legend Biotech (LEGN) Q2 2026 Earnings Call Transcript - theglobeandmail.com
Legend Biotech (NASDAQ:LEGN) Shares Gap Up After Strong Earnings - MarketBeat
Why is Legend Biotech stock surging today? By Investing.com - Investing.com South Africa
Legend Biotech Q2 2026 slides: first profitable quarter, 50% growth - Investing.com
Legend Biotech Q2 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Legend Biotech tops Q2 2026 estimates as stock rises 5% - Investing.com
Why is Legend Biotech stock surging today? - Investing.com
Legend Biotech stock rises 5% on earnings and revenue beat By Investing.com - Investing.com South Africa
Legend Biotech stock rises 5% on earnings and revenue beat - Investing.com
Legend Biotech (NASDAQ:LEGN): What Could Today’s Update Reveal About Cell-Therapy Demand And Manufacturing? - Kalkine Media
Legend Biotech in spotlight: Earnings test Carvykti momentum - Investing.com
1,915,056 Shares in Legend Biotech Corporation Sponsored ADR $LEGN Purchased by Assenagon Asset Management S.A. - MarketBeat
Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Sei Investments Co. Buys 221,899 Shares of Legend Biotech Corporation Sponsored ADR $LEGN - marketbeat.com
Renaissance Technologies LLC Purchases 119,000 Shares of Legend Biotech Corporation Sponsored ADR $LEGN - MarketBeat
Arrowstreet Capital Limited Partnership Acquires 315,176 Shares of Legend Biotech Corporation Sponsored ADR $LEGN - marketbeat.com
H.C. Wainwright reiterates Buy on Legend Biotech stock at $65 - Investing.com
H.C. Wainwright reiterates Buy on Legend Biotech stock, $65 target - Investing.com
Raymond James cuts Legend Biotech stock price target on CEO departure - Investing.com
Why is Legend Biotech stock sliding today? By Investing.com - Investing.com South Africa
Legend Biotech stock falls as CEO Ying Huang steps down By Investing.com - Investing.com South Africa
Legend Biotech stock falls as CEO Ying Huang steps down - Investing.com
Legend Biotech CEO Ying Huang steps down, Alan Bash named interim By Investing.com - Investing.com South Africa
Legend Biotech CEO Ying Huang steps down, Alan Bash named interim - Investing.com
Legend Biotech Announces CEO Transition - Barchart.com
UBS downgrades Legend Biotech stock rating on competition concerns - Investing.com
UBS downgrades Legend Biotech stock rating on competition concerns By Investing.com - Investing.com India
Legend Biotech (NASDAQ:LEGN) Stock Price Up 6.8%Here's Why - MarketBeat
Q4 EPS Estimates for Legend Biotech Cut by HC Wainwright - marketbeat.com
Analysts Offer Insights on Healthcare Companies: Medicinova (MNOV), Legend Biotech (LEGN) and AngioDynamics (ANGO) - The Globe and Mail
H.C. Wainwright reiterates Legend Biotech stock rating on strong Carvykti sales - Investing.com
JPMorgan resumes Legend Biotech stock coverage with neutral rating By Investing.com - Investing.com South Africa
JPMorgan resumes Legend Biotech stock coverage with neutral rating - Investing.com
Legend Biotech (LEGN) Short Interest & Short Float | Updated Jul 2026 - MarketBeat
LEGNLegend Biotech Corp ADR Options - Finviz
Legend Biotech (LEGN) CEO Ying Huang makes charitable gift of 3,382 shares - Stock Titan
Form 144 Legend Biotech Corp For: 30 June By Investing.com - Investing.com India
Form 4 Legend Biotech Corp For: 29 June - Investing.com India
Legend Biotech CEO Huang Ying sells $82,265 in shares By Investing.com - Investing.com South Africa
Form 4 Legend Biotech Corp For: 29 June By Investing.com - Investing.com South Africa
Legend Biotech CEO Huang Ying sells $82,265 in shares - Investing.com
Form 144 Legend Biotech Corp For: 26 June By Investing.com - Investing.com South Africa
Legend Biotech (LEGN) 10K Form and Latest SEC Filings 2026 - MarketBeat
Legend Biotech Corp. Sponsored ADR Actuals & Estimates (NASDAQ:LEGN) - TradingView
Legend Biotech Corp Adr Azioni (LEGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):